CN105833229A - Application of traditional Chinese medicine composition in preparation of medicine for treating myocardial infarction - Google Patents
Application of traditional Chinese medicine composition in preparation of medicine for treating myocardial infarction Download PDFInfo
- Publication number
- CN105833229A CN105833229A CN201610327495.8A CN201610327495A CN105833229A CN 105833229 A CN105833229 A CN 105833229A CN 201610327495 A CN201610327495 A CN 201610327495A CN 105833229 A CN105833229 A CN 105833229A
- Authority
- CN
- China
- Prior art keywords
- parts
- chinese medicine
- medicine composition
- myocardial infarction
- application
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/906—Zingiberaceae (Ginger family)
- A61K36/9068—Zingiber, e.g. garden ginger
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/16—Ginkgophyta, e.g. Ginkgoaceae (Ginkgo family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/285—Aucklandia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/286—Carthamus (distaff thistle)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/484—Glycyrrhiza (licorice)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/537—Salvia (sage)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/57—Magnoliaceae (Magnolia family)
- A61K36/575—Magnolia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/66—Papaveraceae (Poppy family), e.g. bloodroot
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/70—Polygonaceae (Buckwheat family), e.g. spineflower or dock
- A61K36/704—Polygonum, e.g. knotweed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
- A61K36/714—Aconitum (monkshood)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
- A61K36/8962—Allium, e.g. garden onion, leek, garlic or chives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/906—Zingiberaceae (Ginger family)
- A61K36/9066—Curcuma, e.g. common turmeric, East Indian arrowroot or mango ginger
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation, decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
Abstract
The invention discloses application of a traditional Chinese medicine composition in preparation of medicine for treating myocardial infarction, and belongs to the technical field of traditional Chinese medicine. The traditional Chinese medicine composition is prepared from rhizoma corydalis, flos carthami, rhizoma curcumae, radix salvia miltiorrhiza, rhizoma curcumae longae, caulis polygoni multiflori, folium ginkgo bilobae, leaves of moringa oleifera, longstamen onion bulbs, cortex magnoliae officinalis, radix aconiti carmichaeli, rhizoma zingiberis, radix aucklandiae, herba taxilli and licorice roots. The traditional Chinese medicine composition has the effects of promoting blood circulation to remove meridian obstruction, dispersing blood stasis to stop pain, promoting blood circulation to nourish the heart and the like and is significant in treatment effect on the myocardial infarction and high in clinical application and popularization value.
Description
The application is that the application for a patent for invention that applicant Cui Xinming proposes is (invention entitled: a kind of to treat myocardial infarction
Chinese medicine composition and application thereof, Application No.: 2015105253449, filing date: on August 25th, 2015) divisional application.
Technical field
The invention belongs to technical field of traditional Chinese medicines, be specifically related to a kind of Chinese medicine composition medicine in preparation treatment myocardial infarction
In application.
Background technology
Myocardial infarction refers on the basis of coronary artery pathological changes, and blood flow coronarius drastically reduces or interrupts, and makes phase
The cardiac muscle answering position occurs that serious and lasting ischemic occurs ischemic necrosis.The myocardial infarction of more than 90% is crown dynamic
On the basis of pulse atherosclerosis causes luminal stenosis, due to atheromatous plaque increase, Rupture haemorrhag, thrombosis or continuation convulsion
Contraction, causes tube chamber to entirely shut, and blood cannot circulate and cause.The general descending anterior branch the most often involving arteria coroaria sinistra, secondly
It it is the Circumflex branch of arteria coronaria dextra and arteria coroaria sinistra.There is the patient of acute myocardial infarction AMI, the most often have lasting chest
Have an intense pain after bone, generate heat, white blood cell count(WBC) increases, Serum fibrosis markers raises and electrocardiogram reflecting myocardium acute injury, lacks
Blood and downright bad series of features develop, and may occur in which the symptoms such as arrhythmia cordis, shock or heart failure, belong to acute coronary and combine
The serious types of simulator sickness.Most of patients a few days before acute myocardial infarction has weak, and chest is uncomfortable, palpitaition, gas time movable
The premonitory symptom such as urgency, agitation, angina pectoris, wherein with angina pectoris as cardinal symptom.
The complication of myocardial infarction has dysfunction of papillary muscle or fracture, locular wall Aneurysm, blood vessel embolism and miocardial infarction
How rear syndromes etc., occur after falling ill one week.The principle of reatment of myocardial infarction is prevent and treat complication and reduce infarction size.
Clinical treatment myocardial infarction, including primary percutaneous coronary intervention, thromboembolism treatment and drug therapy.Direct coronary artery is got involved
Treatment recurrence rate is high, and the main complication of thromboembolism treatment is hemorrhage, need to be further combined with primary percutaneous coronary intervention, and mesh
The clinical application taboos such as the conventional monobel of front clinic, beta-blocker, Calcilytic are more, there is also curative effect not simultaneously
The defect such as determine, drug side-effect is big.
Myocardial infarction belongs to the categories such as " chest impediment and cardialgia ", " angina pectoris ", " precordial pain with cold limbs " of the traditional Chinese medical science, though motherland's medical literature nothing
Name of disease is recorded, but early has disease clearly to discuss, as " opinion piece when Plain Questions hides gas method " is said: " heart patient, chest pain, discomfort and fullness in the hypochondrium, chest
Pain between back of the body omoplate, pain in the medial sides of both arms ", " Ling Shu Miraculous Pivot or Divine Axis faint disease " is said: " pained very and it is dead to send out sunset, and sunset sends out denier for angina pectoris, bluish colour of the limbs extending up to the elbows and knees
Extremely ", it is simply that the record to patients with acute myocardial infarction shock.The traditional Chinese medical science is thought, the main pathogenesis of myocardial infarction is asthenia in origin and asthenia in superficiality, this
Empty based on the deficiency of vital energy, the deficiency of Yin, mark is real turbid common with the stagnation of the circulation of vital energy, blood stasis, phlegm, and therefore its treatment is also many with benefiting qi and nourishing yin, nourishing blood and promoting blood circulation,
Regulate the flow of vital energy Xie Yu, and promoting blood circulation and stopping pain etc. is main.
The traditional Chinese medical science have accumulated certain experience at relevant diseases such as treatment chest impediment and cardialgias, and the cause of disease for myocardial infarction is sick
Machine understanding is relatively deep, and meanwhile, traditional Chinese medicine possesses that drug side-effect is low and the feature such as treat both principal and secondary aspect of disease, thus in treatment myocardial infarction
Aspect is with the obvious advantage.
Chinese patent application 200810017389.5 discloses a kind of Chinese medicine system treating myocardial infarction induced by myocardial ischemia
Agent, it prepares by the raw material of following portions by weight: ginseng 17-22 part, water baby's 8-12 part, fruit of Chinese magnoliavine 8-12 part, monkshood 8-12
Part, red sage root 8-12 part, seed of Oriental arborvitae 18-22 part, gadfly 8-12 part, tuber of pinellia 8-12 part, pseudo-ginseng 8-12 part, Ligusticum wallichii 8-12 part, musk deer
Fragrant 0.8-1.2 part, Snakegourd Fruit 13-17 part, Longstamen Onion Bulb 13-17 part.This Chinese medicine preparation based on benefit gas, invigorate blood circulation, slit phlegm, in conjunction with doctor trained in Western medicine
The treatment myocardial infarction that causes of myocardial ischemia can obviously reduce the incidence of the complication such as arrhythmia cordis, embolism, but its need with
Other drug partner treatment, and selected cost of material height, be not easy to popularization and application.
Myocardial infarction is the most still a big difficult point of angiocardiology Therapy study.Chinese traditional treatment myocardial infarction, has low
Drug side-effect, the feature such as treat both principal and secondary aspect of disease, have a extensive future, seek a kind of rapid-action, good effect, efficacy stability, low cost and easily
Medicine in the treatment myocardial infarction promoted the use of is this area urgent problem.
Summary of the invention
The technical problem to be solved in the present invention is to provide a kind of Chinese medicine composition in the medicine of preparation treatment myocardial infarction
Application, described Chinese medicine composition has promoting blood circulation and removing obstruction in channels, blood stasis removing analgesic, invigorates blood circulation and nourishes heart and effect of nourishing qi and blood, possesses treatment
Effect is notable, efficacy stability, treat both principal and secondary aspect of disease and the advantage such as application easy to spread.Additionally, the present invention also provides for manufacturing accordingly work
This Chinese medicine is made on the premise of ensureing curative effect and is facilitated easy-to-use finished product preparation by skill.
Chinese medicine composition of the present invention is prepared from by the raw material of following parts by weight:
Corydalis tuber 25-32 part, safflower 23-29 part, curcuma zedoary 18-24 part, red sage root 17-23 part, turmeric 15-21 part, Polygonum multiflower knotweed 19-23
Part, folium ginkgo bilobae 16-22 part, leaf of Moringa 13-18 part, Longstamen Onion Bulb 9-13 part, bark of official magnolia 11-17 part, monkshood 8-13 part, rhizoma zingiberis 12-17 part,
Banksia rose 10-15 part, parasitic loranthus 9-16 part and Radix Glycyrrhizae 7-13 part.
Preferably, described Chinese medicine composition is prepared from by the raw material of following parts by weight:
Corydalis tuber 25 parts, 23 parts of safflower, curcuma zedoary 18 parts, the red sage root 17 parts, 15 parts of turmeric, Polygonum multiflower knotweed 19 parts, folium ginkgo bilobae 16 parts, Moringa
13 parts of leaf, Longstamen Onion Bulb 9 parts, the bark of official magnolia 11 parts, monkshood 8 parts, rhizoma zingiberis 12 parts, the banksia rose 10 parts, parasitic loranthus 9 parts and 7 parts of Radix Glycyrrhizae.
Preferably, described Chinese medicine composition is prepared from by the raw material of following parts by weight:
Corydalis tuber 32 parts, 29 parts of safflower, curcuma zedoary 24 parts, the red sage root 23 parts, 21 parts of turmeric, Polygonum multiflower knotweed 23 parts, folium ginkgo bilobae 22 parts, Moringa
18 parts of leaf, Longstamen Onion Bulb 13 parts, the bark of official magnolia 17 parts, monkshood 13 parts, rhizoma zingiberis 17 parts, the banksia rose 15 parts, parasitic loranthus 16 parts and 13 parts of Radix Glycyrrhizae.
Preferably, described Chinese medicine composition is prepared from by the raw material of following parts by weight:
Corydalis tuber 28 parts, 26 parts of safflower, curcuma zedoary 20 parts, the red sage root 20 parts, 17 parts of turmeric, Polygonum multiflower knotweed 21 parts, folium ginkgo bilobae 19 parts, Moringa
15 parts of leaf, Longstamen Onion Bulb 11 parts, the bark of official magnolia 13 parts, monkshood 10 parts, rhizoma zingiberis 15 parts, the banksia rose 13 parts, parasitic loranthus 12 parts and 9 parts of Radix Glycyrrhizae.
Present invention also offers the preparation method of described Chinese medicine composition, mainly comprise the steps that
(1) take corydalis tuber, the red sage root, the bark of official magnolia, leaf of Moringa, folium ginkgo bilobae and turmeric, pulverize, add according to 8-10 times of medicinal material gross weight
Concentration expressed in percentage by volume is the ethanol solution of 60%-80%, refluxing extraction 2-3 time, and each return time is 2-3h, merges extract,
Reclaiming ethanol, being evaporated to relative density under 60-65 DEG C of environment is the medicinal extract of 1.20-1.25, drying under reduced pressure, mistake after pulverizing
80-100 mesh sieve, obtains medicinal extract fine powder A；
(2) take curcuma zedoary, safflower, monkshood, rhizoma zingiberis, the banksia rose, parasitic loranthus, Longstamen Onion Bulb, Polygonum multiflower knotweed and Radix Glycyrrhizae, pulverize, add medicinal material gross weight
The soak by water 3-4h of amount 6-8 times amount, filters；Filter residue adds the soak by water 2-2.5h of medicinal material gross weight 4-6 times amount, filters；Merge
Twice filtrate, being evaporated to relative density under 60-65 DEG C of environment is the medicinal extract of 1.20-1.25, drying under reduced pressure, mistake after pulverizing
80-100 mesh sieve, obtains medicinal extract fine powder；Fully mix with above-mentioned medicinal extract fine powder A, obtain this Chinese medicine composition.
Utilizing modern general Chinese medicine preparation technology, Chinese medicine composition of the present invention can be made into the finished product preparation of clinical needs,
Such as formulations such as granule, pill, powder, tablet or capsules.
The source of Chinese medicine, nature and flavor used by Chinese medicine composition of the present invention, return through and effect:
Corydalis tuber: this product is the dry tuber of papaveraceae plant corydalis.Taste is pungent, bitter, warm in nature；Return liver, the spleen channel；Promoting blood circulation to remove blood stasis,
Regulating qi-flowing for relieving pain.
Safflower: this product is the dry flower of feverfew safflower.Taste is pungent, warm in nature；The thoughts of returning home, Liver Channel；Invigorate blood circulation and stimulate the menstrual flow, only dissipate the stasis of blood
Bitterly.
Curcuma zedoary: this product is the dry rhizome of zingiberaceous plant zedoary, Guangxi zedoary or RADIX CURCUMAE.Taste is pungent, bitter, warm in nature；Return
Liver, the spleen channel；Blood is broken in promoting the circulation of qi, and disappear long-pending pain relieving.
The red sage root: this product is the dry root and rhizome of the labiate red sage root.Bitter, cold nature；The thoughts of returning home, Liver Channel；The stasis of blood of dispelling is only
Bitterly, invigorate blood circulation and stimulate the menstrual flow, calm the nerves peaceful tired.
Turmeric: this product is the dry rhizome of zingiberaceous plant turmeric.Taste is pungent, bitter, warm in nature；Return spleen, Liver Channel；Broken blood gas is logical
Meridian and relieving pain.
Polygonum multiflower knotweed: this product is rattan or the leaf bine stem of polygonum multiflorum thunb.Taste is sweet, bitter, and property is put down；The thoughts of returning home, Liver Channel；
Nourish heart, calm the nerves, dredging collateral, dispels the wind.
Folium ginkgo bilobae: this product is the blade of Ginkgoaceae plant Ginkgo biloba.Bitter, sweet, puckery, property is put down；The thoughts of returning home, lung, the spleen channel；Invigorate blood circulation foster
The heart, puckery intestines of astringing the lung.
Leaf of Moringa: this product is the dry leaf of Moringaceae plant Moringa.Bitter, slightly warm in nature；Leaf of Moringa have hypoglycemic, lipopenicillinase,
Step-down, antitumor, anti-oxidant and strengthen the effect such as immunity.
Longstamen Onion Bulb: this product is the dry bulb of liliaceous plant Allium macrostemon or Chinese onion.Taste is pungent, bitter, warm in nature；Return lung, stomach, large intestine
Warp；Activating yang and removing abstruction, promoting the circulation of qi is led stagnant.
The bark of official magnolia: this product is the Magnoliacea plant bark of official magnolia or the dry dry hide of Magnolia bilola, Gen Pi and branch skin.Bitter, pungent, property
Temperature；Return spleen, stomach, lung, large intestine channel；Warming the middle warmer and descending qi, eliminating dampness dissolving phlegm.
Monkshood: this product is the processed goods of the sub-root of the ranunculaceae plant rhizome of Chinese monkshood.Taste is pungent, sweet, property heat；The thoughts of returning home, kidney, the spleen channel；Return
Sun is rescued inverse, mends fire supporing yang, by wind-cold damp pathogen.
Rhizoma zingiberis: this product is the dry rhizome of zingiber.Taste is pungent, property heat；Return spleen, stomach, kidney, the heart, lung channel；Temperature dissipates
Cold, Hui Yang promotes blood circulation, eliminating dampness dissolving phlegm.
The banksia rose: this product is the dry root of the feverfew banksia rose.Taste is pungent, bitter, warm in nature；Return spleen, stomach, large intestine, three burnt, gallbladder channels；
Promoting qi circulation and relieving pain, reinforcing spleen to promote digestion.
Parasitic loranthus: this product is the dry stem and branch with leaf of Loranthaceae plant parasitic loranthus.Bitter, sweet, property is put down；Return liver, kidney channel；
Filling liver kidney, strengthening the bones and muscles, wines used as antirheumatic, stimulate the menstrual flow network, benefit blood, antiabortive.
Radix Glycyrrhizae: this product is glycyrrhizic legume, swollen fruit Radix Glycyrrhizae or the dry root of glycyrrhiza glabra.Taste is sweet, and property is put down；The thoughts of returning home, lung,
Spleen, stomach warp；Invigorate the spleen and benefit qi, clearing heat and detoxicating, expelling phlegm and arresting coughing, relieving spasm to stop pain, coordinating the drug actions of a prescription.
The prescription analysis of medicament composing prescription of the present invention:
Medicament composing prescription of the present invention is with corydalis tuber and safflower as monarch drug in a prescription, and promoting blood circulation to remove blood stasis, stimulate the menstrual flow network, regulating qi-flowing for relieving pain；With curcuma zedoary, the red sage root,
Turmeric, Polygonum multiflower knotweed and folium ginkgo bilobae are ministerial drug, broken blood gas, inducing meastruation to relieve menalgia, invigorate blood circulation and nourish heart, and calm the nerves peaceful tired；With leaf of Moringa, Longstamen Onion Bulb,
The bark of official magnolia, monkshood, rhizoma zingiberis, the banksia rose and parasitic loranthus are adjutant, promoting the circulation of qi in temperature, and liver-kidney tonifying activates yang and remove abstruction, and promoting the circulation of qi is led stagnant, hypoglycemic,
Blood fat and blood pressure；With Radix Glycyrrhizae for making medicine, invigorate the spleen and benefit qi, clearing heat and detoxicating, coordinating the drug actions of a prescription, make all medicines arrange in pairs or groups, synergy, jointly reach
To promoting blood circulation and removing obstruction in channels, blood stasis removing analgesic, to invigorate blood circulation and nourish heart, liver-kidney tonifying, reducing blood lipid, hypoglycemic and hypotensive effect, to myocardial infarction
There is the most significant result for the treatment of.
Creatine kinase (CK), aspartate amino transferase (AST) and lactic dehydrogenase (LDH) are present in cardiac muscle
Intracellular protease, when cellular damage or necrosis, CK, AST, LDH just can be discharged into blood from intracellular, therefore survey
Determine serum CK, AST, LDH can be as the indexs of reflecting myocardium degree of necrosis.Chinese medicine composition of the present invention is to myocardial infarction model
The experimental study of rat shows, Chinese medicine composition of the present invention can significantly improve CK in the serum of myocardial infarction model rat, AST,
The content of LDH, compares with positive controls, Chinese medicine composition A group high dose group of the present invention, B group high dose group and the height of C group,
The action effect of middle dosage group is all significantly better than positive controls.This illustrates traditional Chinese medicine composition for treating myocardial infarction effect of the present invention
Significantly, clinical value is high.
Compared with prior art, Chinese medicine composition of the present invention has a following technical advantage:
(1) Chinese medicine composition medicinal material of the present invention and dose compatibility science, synergy is strong, has the most promoting blood circulation and removing obstruction in channels, dissipates the stasis of blood
Pain relieving, invigorates blood circulation and nourishes heart and effect of liver-kidney tonifying, and treatment myocardial infarction is with strong points, and effect is comprehensively.
(2) pharmacological testing proves, Chinese medicine composition of the present invention can significantly reduce lactic acid in myocardial infarction model rat blood serum
Dehydrogenase (LDH), creatine kinase (CK) and the content of paddy transaminase (AST), thus prove that it can significantly improve myocardial necrosis
Degree, has significant protective effect to myocardial ischemia, and treatment myocardial infarction effect is notable.
(3) Chinese medicine composition of the present invention is pure Chinese medicinal preparation, and drug side-effect is low, is clinically used for treating myocardial infarction onset
Hurry up, good effect, also there is the advantage such as efficacy stability and application easy to spread simultaneously.
Detailed description of the invention
Hereinafter will further describe the present invention by specific embodiment, the present invention is not limited only to following example.At this
In the range of invention or without departing from present disclosure, spirit and scope, change that the present invention is carried out, combine or replace
Change, will be apparent to the person skilled in the art, be included within the scope of the present invention.
Embodiment 1
The embodiment of the present invention 1 Chinese medicine composition is prepared from by the raw material of following parts by weight:
Corydalis tuber 25 parts, 23 parts of safflower, curcuma zedoary 18 parts, the red sage root 17 parts, 15 parts of turmeric, Polygonum multiflower knotweed 19 parts, folium ginkgo bilobae 16 parts, Moringa
13 parts of leaf, Longstamen Onion Bulb 9 parts, the bark of official magnolia 11 parts, monkshood 8 parts, rhizoma zingiberis 12 parts, the banksia rose 10 parts, parasitic loranthus 9 parts and 7 parts of Radix Glycyrrhizae.
Preparation method is as follows:
(1) take corydalis tuber, the red sage root, the bark of official magnolia, leaf of Moringa, folium ginkgo bilobae and turmeric, pulverize, according to 10 times of addition bodies of medicinal material gross weight
Long-pending percentage concentration is the ethanol solution of 70%, refluxing extraction 3 times, and each return time is 2h, merges extract, reclaims ethanol, subtracts
It is the medicinal extract of 1.25 that pressure is concentrated into relative density under 65 DEG C of environment, drying under reduced pressure, crosses 100 mesh sieves, obtain medicinal extract fine powder after pulverizing
A；
(2) take curcuma zedoary, safflower, monkshood, rhizoma zingiberis, the banksia rose, parasitic loranthus, Longstamen Onion Bulb, Polygonum multiflower knotweed and Radix Glycyrrhizae, pulverize, add medicinal material gross weight
Measure the soak by water 3h of 6 times amount, filter；Filter residue adds the soak by water 2h of medicinal material gross weight 4 times amount, filters；Merge twice filtrate, subtract
It is the medicinal extract of 1.25 that pressure is concentrated into relative density under 65 DEG C of environment, drying under reduced pressure, crosses 100 mesh sieves, obtain medicinal extract thin after pulverizing
Powder；Fully mix with above-mentioned medicinal extract fine powder A, obtain this Chinese medicine composition fine powder.
(3) above-mentioned fine powder is added starch dilution in the ratio of 4:1, soak by spray-on process with 60% ethanol, softwood processed, cross 14
Mesh sieve obtains wet grain, and wet grain is 60 DEG C of drying, and dry granular crosses the 14 whole grains of mesh sieve, and the magnesium stearate adding dry granular gross weight 0.5% mixes
Even, compressing tablet, every tablet weight 0.25g, coating, obtain Chinese medicine composition tablet of the present invention.
Embodiment 2
The embodiment of the present invention 2 Chinese medicine composition is prepared from by the raw material of following parts by weight:
Corydalis tuber 32 parts, 29 parts of safflower, curcuma zedoary 24 parts, the red sage root 23 parts, 21 parts of turmeric, Polygonum multiflower knotweed 23 parts, folium ginkgo bilobae 22 parts, Moringa
18 parts of leaf, Longstamen Onion Bulb 13 parts, the bark of official magnolia 17 parts, monkshood 13 parts, rhizoma zingiberis 17 parts, the banksia rose 15 parts, parasitic loranthus 16 parts and 13 parts of Radix Glycyrrhizae.
Preparation method is with embodiment 1.
Embodiment 3
The embodiment of the present invention 3 Chinese medicine composition is prepared from by the raw material of following parts by weight:
Corydalis tuber 28 parts, 26 parts of safflower, curcuma zedoary 20 parts, the red sage root 20 parts, 17 parts of turmeric, Polygonum multiflower knotweed 21 parts, folium ginkgo bilobae 19 parts, Moringa
15 parts of leaf, Longstamen Onion Bulb 11 parts, the bark of official magnolia 13 parts, monkshood 10 parts, rhizoma zingiberis 15 parts, the banksia rose 13 parts, parasitic loranthus 12 parts and 9 parts of Radix Glycyrrhizae.
Preparation method is as follows:
(1) take corydalis tuber, the red sage root, the bark of official magnolia, leaf of Moringa, folium ginkgo bilobae and turmeric, pulverize, according to 10 times of addition bodies of medicinal material gross weight
Long-pending percentage concentration is the ethanol solution of 70%, refluxing extraction 2 times, and each return time is 2h, merges extract, reclaims ethanol, subtracts
It is the medicinal extract of 1.20 that pressure is concentrated into relative density under 60 DEG C of environment, drying under reduced pressure, crosses 100 mesh sieves, obtain medicinal extract fine powder after pulverizing
A；
(2) take curcuma zedoary, safflower, monkshood, rhizoma zingiberis, the banksia rose, parasitic loranthus, Longstamen Onion Bulb, Polygonum multiflower knotweed and Radix Glycyrrhizae, pulverize, add medicinal material gross weight
Measure the soak by water 3h of 8 times amount, filter；Filter residue adds the soak by water 2h of medicinal material gross weight 5 times amount, filters；Merge twice filtrate, subtract
It is the medicinal extract of 1.25 that pressure is concentrated into relative density under 60 DEG C of environment, drying under reduced pressure, crosses 100 mesh sieves, obtain medicinal extract thin after pulverizing
Powder；Fully mix with above-mentioned medicinal extract fine powder A, obtain this Chinese medicine composition fine powder；
(3) by filling for above-mentioned fine powder capsule, every seed lac capsule drug containing 0.55g, obtain Chinese medicinal composition capsules agent of the present invention.
Embodiment 4
The embodiment of the present invention 4 Chinese medicine composition is prepared from by the raw material of following parts by weight:
Corydalis tuber 27 parts, 25 parts of safflower, curcuma zedoary 23 parts, the red sage root 17 parts, 17 parts of turmeric, Polygonum multiflower knotweed 21 parts, folium ginkgo bilobae 18 parts, Moringa
15 parts of leaf, Longstamen Onion Bulb 11 parts, the bark of official magnolia 13 parts, monkshood 10 parts, rhizoma zingiberis 14 parts, the banksia rose 12 parts, parasitic loranthus 11 parts and 13 parts of Radix Glycyrrhizae.
Preparation method is with embodiment 3.
Chinese medicine composition pharmacodynamic study of the present invention:
Test one: the Chinese medicine composition of the present invention experimental study to myocardial infarction model rat
1, test principle: lactic dehydrogenase (LDH), creatine kinase (CK) and paddy transaminase (AST) are three kinds of main myocardium enzyme.
Under normal circumstances, myocardium enzyme content in serum is the lowest, when myocardial ischemia and necrosis or permeability of cell membrane increase, and myocardium enzyme
Just being discharged into blood from cardiac muscle cell, different according to cardiac muscle institute degree of impairment, the amplitude that in serum, enzyme raises is the most different, therefore
The generation of reflecting myocardium infarct and the size of focus can be come by the changes of contents of LDH, CK, AST in serum.Cardiac muscle clinically
The assay of enzyme is usually used in the auxiliary diagnosis of myocardial infarction.This test is by studying Chinese medicine composition of the present invention to myocardial infarction
In rat model serum, the impact of LDH, CK and AST level proves its result for the treatment of to myocardial infarction.
2, experimental animal: regular grade SD rat 130, body weight 230-280g, male and female half and half, is randomly divided into 13 groups, often group
10.
3, trial drug and dosage regimen:
A group: trial drug is the Chinese medicine composition fine powder of the embodiment of the present invention 1, being deployed into concentration with water is 0.6g/ml, 0.4g/
The solution of ml and 0.2g/ml, standby.Take 3 groups of myocardial infarction model rats, be labeled as A group high dose group (dosage 2.4g/kg),
Middle dosage group (dosage 1.6g/kg) and low dose group (dosage 0.8g/kg), high dose group concentration is that the medicine of 0.6g/ml is molten
Liquid is administered, and middle dosage group concentration is that the drug solution of 0.4g/ml is administered, and low dose group concentration is that the medicine of 0.2g/ml is molten
Liquid is administered, according to dosage gavage every day 1 time, successive administration 14 days.
B group: trial drug is the Chinese medicine composition fine powder of the embodiment of the present invention 2, and dosage regimen is with A group.
C group: trial drug is the Chinese medicine composition fine powder of the embodiment of the present invention 3, and dosage regimen is with A group.
Positive controls: positive control drug is the happy capsule of Moschus heart and brain (traditional Chinese medicines quasi-word traditional Chinese medicines quasi-word Z20050054, Jilin
Save great Jun medicine company limited company), after going capsule shells, content water is deployed into the solution of 0.6g/ml, takes 1 group of cardiac muscle stalk
Dead rat model, by dosage gastric infusion every day 1 time of 2.4g/kg, successive administration 14 days.
Model control group: take 1 group of myocardial infarction model rat, isometric(al) physiological saline gavage every day 1 time, continuous gavage 14
My god.
Sham-operation group: take 1 group of rat, isometric(al) physiological saline gavage every day 1 time after sham-operation, continuous gavage 14 days.
Normal group: take 1 group of rat, isometric(al) physiological saline gavage every day 1 time, continuous gavage 14 days.
4, the foundation of rat model of myocardial infarction:
Rat pre-operative anxiety 12h, 10% chloraldurate (300mg/kg) intraperitoneal injection of anesthesia, back of the body position is fixed, and connects limb leads,
Record Rat Ecg.Neck and front depilation, routine disinfection, connect animal breath assisted respiartion, tidal volume through trachea cannula
3ml/100g rat, respiratory quotient 3:1,70 times/min of respiratory rate, successively opens chest through left front para T the 3rd, 4 intercostals, exposes the heart
Dirty, cut off pericardium, have a common boundary slightly to descend at 1-2mm with 6-0 silk thread following coronary artery occlusion descending anterior branch at left auricle of heart and pulmonary conus
Making myocardial infarction model, cardiac muscle color below ligature seen from naked eyes loses color and heartbeat weakens, and is modelling
Success criterion.Rapidly heart being put back to thoracic cavity after ligation, subsequently extrusion chest intracavity gas, layer-by-layer suture closes chest.Postoperative
30min Rat Ecg occurs that lead R wave-amplitude step-down, ST section of II, III, AVL, AVF is raised, thus further determined that model
It is successfully established.Ibid, silk thread passes from coronary artery but does not ligatures rats in sham-operated group operation method.Postoperative every rat flesh
Anti-infective 3 days of meat injection penicillin 400,000 unit.
5, result of the test: be administered after terminating, will carry out abdominal aortic blood after rat anesthesia, measure LDH in serum, CK,
The content of AST, result is as shown in table 1.
The impact on myocardial infarction model rat of table 1 Chinese medicine composition of the present invention
Note: compare with Normal group,&P ＜ 0.05,&&P ＜ 0.01；Compare with model control group,*P ＜ 0.05,**P ＜ 0.01；
Compare with positive controls,#P ＜ 0.05,##P ＜ 0.01.
6, conclusion (of pressure testing):
Test data shows, compares with Normal group, LDH, CK, AST content of rats in sham-operated group without the change of conspicuousness,
And the equal conspicuousness of LDH, CK, AST content of myocardial infarction model group rat increases, with the serum cardiac of human myocardium's infarct disease
Enzyme changes of contents is consistent, can be used for studying the Chinese medicine composition of the present invention result for the treatment of to myocardial infarction.
Comparing with model control group, Chinese medicine composition of the present invention can significantly improve the serum cardiac of myocardial infarction model rat
The action effect of the dosage group high, middle of enzyme content, wherein A group high dose group, B group high dose group and C group is all significantly better than sun
Property control group, other dosage groups also can reduce the content of LDH, CK, AST in rat blood serum to a certain extent.This illustrates this
Bright Chinese medicine composition is notable to the result for the treatment of of myocardial infarction, can be used for the clinical treatment of myocardial infarction.
Claims (6)
1. the Chinese medicine composition application in the medicine of preparation treatment myocardial infarction, it is characterised in that described Chinese drug-treated group
Compound is prepared from by the raw material of following parts by weight: corydalis tuber 25-32 part, safflower 23-29 part, curcuma zedoary 18-24 part, the red sage root
17-23 part, turmeric 15-21 part, Polygonum multiflower knotweed 19-23 part, folium ginkgo bilobae 16-22 part, leaf of Moringa 13-18 part, Longstamen Onion Bulb 9-13 part, the bark of official magnolia
11-17 part, monkshood 8-13 part, rhizoma zingiberis 12-17 part, banksia rose 10-15 part, parasitic loranthus 9-16 part and Radix Glycyrrhizae 7-13 part.
2. the Chinese medicine composition as claimed in claim 1 application in the medicine of preparation treatment myocardial infarction, it is characterised in that
Described Chinese medicine composition is prepared from by the raw material of following parts by weight: corydalis tuber 25 parts, 23 parts of safflower, curcuma zedoary 18 parts, pellet
Join 17 parts, 15 parts of turmeric, Polygonum multiflower knotweed 19 parts, folium ginkgo bilobae 16 parts, leaf of Moringa 13 parts, Longstamen Onion Bulb 9 parts, the bark of official magnolia 11 parts, monkshood 8 parts, dry
Ginger 12 parts, the banksia rose 10 parts, parasitic loranthus 9 parts and 7 parts of Radix Glycyrrhizae.
3. the Chinese medicine composition as claimed in claim 1 application in the medicine of preparation treatment myocardial infarction, it is characterised in that
Described Chinese medicine composition is prepared from by the raw material of following parts by weight: corydalis tuber 32 parts, 29 parts of safflower, curcuma zedoary 24 parts, pellet
Join 23 parts, 21 parts of turmeric, Polygonum multiflower knotweed 23 parts, folium ginkgo bilobae 22 parts, leaf of Moringa 18 parts, Longstamen Onion Bulb 13 parts, the bark of official magnolia 17 parts, monkshood 13 parts,
Rhizoma zingiberis 17 parts, the banksia rose 15 parts, parasitic loranthus 16 parts and 13 parts of Radix Glycyrrhizae.
4. the Chinese medicine composition as claimed in claim 1 application in the medicine of preparation treatment myocardial infarction, it is characterised in that
Described Chinese medicine composition is prepared from by the raw material of following parts by weight: corydalis tuber 28 parts, 26 parts of safflower, curcuma zedoary 20 parts, pellet
Join 20 parts, 17 parts of turmeric, Polygonum multiflower knotweed 21 parts, folium ginkgo bilobae 19 parts, leaf of Moringa 15 parts, Longstamen Onion Bulb 11 parts, the bark of official magnolia 13 parts, monkshood 10 parts,
Rhizoma zingiberis 15 parts, the banksia rose 13 parts, parasitic loranthus 12 parts and 9 parts of Radix Glycyrrhizae.
5. the application in the medicine of preparation treatment myocardial infarction of the Chinese medicine composition as described in claim 1-4 is arbitrary, it is special
Levy and be: described Chinese medicine composition is made into granule, pill, powder, tablet or capsule.
6. the application in the medicine of preparation treatment myocardial infarction of the Chinese medicine composition as described in claim 1-4 is arbitrary, it is special
Levying and be, the preparation method of described Chinese medicine composition comprises the following steps:
(1) take corydalis tuber, the red sage root, the bark of official magnolia, leaf of Moringa, folium ginkgo bilobae and turmeric, pulverize, add according to 8-10 times of medicinal material gross weight
Concentration expressed in percentage by volume is the ethanol solution of 60%-80%, refluxing extraction 2-3 time, and each return time is 2-3h, merges extract,
Reclaiming ethanol, being evaporated to relative density under 60-65 DEG C of environment is the medicinal extract of 1.20-1.25, drying under reduced pressure, mistake after pulverizing
80-100 mesh sieve, obtains medicinal extract fine powder A；
(2) take curcuma zedoary, safflower, monkshood, rhizoma zingiberis, the banksia rose, parasitic loranthus, Longstamen Onion Bulb, Polygonum multiflower knotweed and Radix Glycyrrhizae, pulverize, add medicinal material gross weight
The soak by water 3-4h of amount 6-8 times amount, filters；Filter residue adds the soak by water 2-2.5h of medicinal material gross weight 4-6 times amount, filters；Merge
Twice filtrate, being evaporated to relative density under 60-65 DEG C of environment is the medicinal extract of 1.20-1.25, drying under reduced pressure, mistake after pulverizing
80-100 mesh sieve, obtains medicinal extract fine powder；Fully mix with above-mentioned medicinal extract fine powder A, obtain Chinese medicine composition.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610327495.8A CN105833229A (en) | 2015-08-25 | 2015-08-25 | Application of traditional Chinese medicine composition in preparation of medicine for treating myocardial infarction |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510525344.9A CN105056192A (en) | 2015-08-25 | 2015-08-25 | Traditional Chinese medicine composition for treating myocardial infarction and application thereof |
| CN201610327495.8A CN105833229A (en) | 2015-08-25 | 2015-08-25 | Application of traditional Chinese medicine composition in preparation of medicine for treating myocardial infarction |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510525344.9A Division CN105056192A (en) | 2015-08-25 | 2015-08-25 | Traditional Chinese medicine composition for treating myocardial infarction and application thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN105833229A true CN105833229A (en) | 2016-08-10 |
Family
ID=54485861
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510525344.9A Withdrawn CN105056192A (en) | 2015-08-25 | 2015-08-25 | Traditional Chinese medicine composition for treating myocardial infarction and application thereof |
| CN201610327495.8A Withdrawn CN105833229A (en) | 2015-08-25 | 2015-08-25 | Application of traditional Chinese medicine composition in preparation of medicine for treating myocardial infarction |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510525344.9A Withdrawn CN105056192A (en) | 2015-08-25 | 2015-08-25 | Traditional Chinese medicine composition for treating myocardial infarction and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (2) | CN105056192A (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105412517A (en) * | 2015-12-22 | 2016-03-23 | 暨南大学 | Traditional Chinese medicine composition containing Chinese mugwort leaves and used for treating myocardial infarction |
| CN105816830A (en) * | 2016-03-24 | 2016-08-03 | 杨万勇 | Traditional Chinese medicine preparation for treating hypertrophic obstructive cardiomyopathy and preparation method thereof |
| CN105748931A (en) * | 2016-04-14 | 2016-07-13 | 青岛市黄岛区中医医院 | Traditional Chinese medicine for treating acute myocardial infraction combined with shock and preparation method |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101229314B (en) * | 2008-01-18 | 2011-11-16 | 杨子驿 | Chinese traditional medicine preparation for treating myocardial infarction induced by myocardial ischemia |
| CN104096212A (en) * | 2014-08-12 | 2014-10-15 | 崔银方 | Traditional Chinese medicine application for treating myocardial infarction and application for same |
-
2015
- 2015-08-25 CN CN201510525344.9A patent/CN105056192A/en not_active Withdrawn
- 2015-08-25 CN CN201610327495.8A patent/CN105833229A/en not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| CN105056192A (en) | 2015-11-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104606513A (en) | Traditional Chinese medicine for treating cardiovascular and cerebrovascular diseases and preparation method of traditional Chinese medicine | |
| CN104873705A (en) | Medicinal composition for treating angina pectoris of coronary heart disease and application thereof | |
| CN105833229A (en) | Application of traditional Chinese medicine composition in preparation of medicine for treating myocardial infarction | |
| CN103989970B (en) | A kind of Chinese medicine composition treating hypertension | |
| CN108619355A (en) | A kind of antitumor Chinese and preparation method thereof | |
| CN105311492A (en) | Medicine for treating coronary atherosclerotic heart disease | |
| CN105343761A (en) | Traditional Chinese medicine composition for treating myocardial infarction and preparation method thereof | |
| CN104147346A (en) | Traditional Chinese medicinal compound for treating coronary diffuse lesion angina | |
| CN102988938A (en) | Traditional Chinese medicine composition for treating arrhythmia or atrial fibrillation and preparation method thereof | |
| CN105664053A (en) | Traditional Chinese medicine composition for treating calluses on puncture of internal arteriovenous fistula of maintenance hemodialysis patient | |
| CN104888133A (en) | Traditional Chinese medicine composition for treatment of coronary heart disease | |
| CN110882347A (en) | A Chinese medicinal composition for treating cardiovascular diseases | |
| CN104147441A (en) | Traditional Chinese medicine for treating yang-deficiency water-flooding type chronic cardiac insufficiency and preparation method thereof | |
| CN104117018A (en) | Traditional Chinese medicine composition for treating coronary heart disease | |
| CN108938718A (en) | A kind of preparation method of Chinese medicine composition and its preparation for treating headstroke | |
| CN108379510A (en) | A kind of Chinese medicine composition for treating angiocardiopathy | |
| CN101152247A (en) | Pharmaceutical composition for cardiovascular and cerebrovascular diseases and method for preparing the same | |
| CN102488860B (en) | Traditional Chinese medicine composition for treating chronic uremia and preparation method thereof | |
| CN105362610A (en) | Traditional Chinese medicine composition for treating coronary artery diseases | |
| CN105233157A (en) | Chinese medicine composition for treating myocardial infarction and preparation method thereof | |
| CN105878921A (en) | Traditional Chinese medicine composition for treating myocardial infarction and preparation method thereof | |
| CN105381175A (en) | Application of traditional Chinese medicine composition in preparation of drugs for treating coronary artery diseases | |
| CN105031286A (en) | Chinese herb preparation for treating iron-deficiency anemia and preparation method thereof | |
| CN105796881A (en) | Medicine composition containing folium artemisiae argyi and used for treating pyemia and preparation method of medicine composition | |
| CN105311425A (en) | Application of pharmaceutical composition containing folium artemisiae argyi in preparing medicine for treating myocardial infarction |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WW01 | Invention patent application withdrawn after publication | ||
| WW01 | Invention patent application withdrawn after publication |
Application publication date: 20160810 |